

The Nurses' Role in Differentiating and Treating Infusion and Hypersensitivity Reactions

References:

1. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *J Clin Oncol*. 2012 May 10;30(14):1663-9.
2. Leukemia and Lymphoma Society. ALL Treatment Outcomes. <https://www.lls.org/leukemia/acute-lymphoblastic-leukemia/treatment/treatment-outcomes>. Accessed October 11, 2023.
3. Douer D, Gökbuget N, Stock W, Boissel N. Optimizing use of L-asparaginase-based treatment of adults with acute lymphoblastic leukemia. *Blood Rev*. 2022 May;53:100908.
4. Aldoss I, Douer D. How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemia. *Blood*. 2020;135(13):987-995. doi:10.1182/blood.2019002477
5. Gupta S, Wang C, Raetz EA, et al. Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. *Journal of Clinical Oncology*. 2020;38(17):1897-1905. doi:10.1200/JCO.19.03024
6. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol*. 1996 Jan;14(1):18-24.
7. Angiolillo AL, Schore RJ, Kairalla JA, et al. Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932. *J Clin Oncol*. 2021 May 1;39(13):1437-1447.
8. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli* L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. *Lancet Oncol*. 2015 Dec;16(16):1677-90.
9. Jeha S, Pei D, Choi J, et al. Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16. *J Clin Oncol*. 2019 Dec 10;37(35):3377-3391.
10. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study. *J Clin Oncol*. 2019 Jul 1;37(19):1638-1646.

Provided by MediCom Worldwide, Inc.

Supported by an independent medical education grant from Jazz Pharmaceuticals.